Trials / Completed
CompletedNCT00288691
Menorrhagia Study in Women With Treatment-resistant Menorrhagia
A Multi-center, Double-blind, Placebo-controlled, Randomized, Parallel Group Study to Evaluate the Effects of Different Doses of SH T 00127B in Women With Treatment-resistant Menorrhagia Aged 30 to 55 Years After Daily Oral Administration of Multiple Doses for 35 up to 50 Days
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 30 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to explore effects of the investigational product for the treatment of treatment-resistant menorrhagia without organic cause.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asoprisnil (BAY86-5294) | 5mg/day |
| DRUG | Asoprisnil (BAY86-5294) | 10mg/day |
| DRUG | Asoprisnil (BAY86-5294) | 25mg/day |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2001-11-01
- Completion
- 2004-01-01
- First posted
- 2006-02-08
- Last updated
- 2014-12-30
Source: ClinicalTrials.gov record NCT00288691. Inclusion in this directory is not an endorsement.